Financial Perspectives’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.5K Hold
88
﹤0.01% 471
2025
Q4
$16.7K Hold
88
﹤0.01% 459
2025
Q3
$14.6K Hold
88
﹤0.01% 474
2025
Q2
$13.5K Hold
88
﹤0.01% 472
2025
Q1
$13.8K Hold
88
﹤0.01% 461
2024
Q4
$13.8K Hold
88
﹤0.01% 463
2024
Q3
$15.6K Hold
88
0.01% 420
2024
Q2
$14.8K Hold
88
0.01% 416
2024
Q1
$14.6K Hold
88
0.01% 419
2023
Q4
$14.5K Hold
88
0.01% 419
2023
Q3
$13.7K Hold
88
0.01% 407
2023
Q2
$13.7K Hold
88
0.01% 412
2023
Q1
$14.3K Hold
88
0.01% 407
2022
Q4
$14.1K Hold
88
0.01% 400
2022
Q3
$12.4K Hold
88
0.01% 408
2022
Q2
$12.8K Hold
88
0.01% 410
2022
Q1
$14.3K Hold
88
0.01% 414
2021
Q4
$16.7K Hold
88
0.01% 381
2021
Q3
$17.8K Hold
88
0.01% 369
2021
Q2
$17.7K Sell
88
-15,351
-99% -$2.86M 0.01% 391
2021
Q1
$88K Buy
15,439
+15,351
+17,444% +$2.78M ﹤0.01% 524
2020
Q4
$14.9K Hold
88
0.01% 361
2020
Q3
$14.3K Hold
88
0.01% 332
2020
Q2
$14.3K Hold
88
0.01% 312
2020
Q1
$11.3K Hold
88
0.01% 311
2019
Q4
$12.3K Buy
+88
New +$11.6K 0.01% 310

Other funds holding BBH

Financial Perspectives's BBH Position: Q1 2026 in Review

Financial Perspectives held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 88 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Financial Perspectives first reported a position in BBH in Q4 2019 and has held it in 26 quarters since. The position peaked at $88K in Q1 2021. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Financial Perspectives held 88 shares of VanEck Biotech ETF worth $16.5K as of Q1 2026.
  • Financial Perspectives left its VanEck Biotech ETF share count unchanged in Q1 2026.
  • VanEck Biotech ETF made up ﹤0.01% of Financial Perspectives's portfolio in Q1 2026, its #471 holding.
  • Financial Perspectives first reported a position in VanEck Biotech ETF in Q4 2019 and has held it in 26 quarters since.
  • Financial Perspectives's VanEck Biotech ETF position peaked at $88K in Q1 2021.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Financial Perspectives's 13F filing for Q1 2026, filed 11 May 2026.